All resolutions concerning other medicinal products and diagnostics

Upadacitinib Rinvoq® AbbVie Deutschland GmbH Diseases of the musculoskeletal diseases OTHER Rheumatoid arthritis (RA) 34% Indication for considerable additional benefit
Dupilumab (4) Dupixent® Sanofi-Aventis Deutschland GmbH Respiratory diseases OTHER Chronic rhinosinusitis with nasal polyps 100% Hint for considerable additional benefit
Belimumab (2) Benlysta® GlaxoSmithKline GmbH & Co. KG Diseases of the musculoskeletal diseases OTHER Systemic Lupus Erythematodes (SLE) 100% Indication for non-quantifiable additional benefit
Dupilumab (2) Dupixent® Sanofi-Aventis Deutschland GmbH Respiratory diseases OTHER Asthma 100% no additional benefit
Dupilumab (3) Dupixent® Sanofi-Aventis Deutschland GmbH Skin diseases OTHER Atopic dermatitis 100% Indication for non-quantifiable additional benefit
Andexanet alfa Ondexxya® Portola Deutschland GmbH Hematopoietic diseases OTHER Anticoagulation antidote (factor Xa) 100% no additional benefit
Ravulizumab Ultomiris® Alexion Pharma Germany GmbH Hematopoietic diseases OTHER Paroxysmal hemoglobinuria 100% no additional benefit
Risankizumab Skyrizi® AbbVie Deutschland GmbH & Co. KG Skin diseases OTHER Plaque psoriasis 82% Proof of considerable additional benefit
Voretigen Neparvovec Luxturna® Novartis Pharma GmbH Eye diseases OTHER ORPHAN Retinal dystrophy 100% Indication for considerable additional benefit
Regadenoson (2) Rapiscan® GE Healthcare Buchler GmbH & Co. KG Other OTHER Stenosis, Fractional Flow Reserve Measurement (FFR) 100% no additional benefit
Lanadelumab Takhzyro® Shire Deutschland GmbH, Teil der Takeda Group Other OTHER ORPHAN Hereditary angioedema (HAE) 100% Hint for considerable additional benefit
Fluticasonfuroat / Umeclidinium / Vilanterol (2) Trelegy Ellipta® GlaxoSmithKline GmbH & Co. KG Respiratory diseases OTHER Chronic obstructive pulmonary disease (COPD) 100% no additional benefit
Tildrakizumab Ilumetri® Almirall Hermal GmbH Skin diseases OTHER Plaque psoriasis 100% no additional benefit
Ocriplasmin (2) Jetrea® Oxurion NV Eye diseases OTHER Vitreomacular traction (VMT) 94% Indication for minor additional benefit
Mepolizumab (2) Nucala® GlaxoSmithKline GmbH & Co. KG Respiratory diseases OTHER Eosinophilic Asthma 100% no additional benefit
Tofacitinib (4) Xeljanz® Pfizer Pharma GmbH Diseases of the musculoskeletal diseases OTHER Psoriatic arthritis 69% Indication for minor additional benefit
Tofacitinib (3) Xeljanz® Pfizer Pharma GmbH Diseases of the digestive system OTHER Ulcerative colitis 100% no additional benefit
Ingenolmebutat (2, reassessment) Picato® LEO Pharma GmbH Skin diseases OTHER Actinic keratosis 50% Indication for non-quantifiable additional benefit
Darvadstrocel Alofisel® Takeda Pharma Vertrieb GmbH & Co. KG Diseases of the digestive system OTHER ORPHAN Morbus Crohn associated perianal fistulas 100% non-quantifiable additional benefit
Tofacitinib (2, reassessment) Xeljanz® Pfizer Pharma GmbH Diseases of the musculoskeletal diseases OTHER Rheumatoid arthritis (RA) 100% no additional benefit
Glycopyrroniumbromid Sialanar® Proveca Limited Other OTHER Sialorrhea 100% Indication for non-quantifiable additional benefit
Fluticasonfuroat / Umeclidinium / Vilanterol Trelegy Ellipta® GlaxoSmithKline GmbH & Co. KG Respiratory diseases OTHER Chronic obstructive pulmonary disease (COPD) 100% no additional benefit
Ixekizumab (2) Taltz® Lilly Deutschland GmbH Diseases of the musculoskeletal diseases OTHER Psoriatic arthritis 35% Indication for minor additional benefit
Benralizumab Fasenra® AstraZeneca GmbH Respiratory diseases OTHER Eosinophilic asthma 50% Indication for minor additional benefit
Fluticasonfuroat / Vilanterol-Trifenatat (2, reassessment) Relvar® Ellipta® GlaxoSmithKline GmbH & Co. KG Respiratory diseases OTHER Asthma 100% no additional benefit
Allogene, genetisch modifizierte T-Zellen Zalmoxis® Dompé farmaceutici S.p.A Oncological diseases OTHER ORPHAN Hematopoietic stem cell transplantation, add-on therapy 100% Hint for non-quantifiable additional benefit
Dupilumab Dupixent® Sanofi-Aventis Deutschland GmbH Skin diseases OTHER Atopic dermatitis 100% Hint for considerable additional benefit
Guselkumab Tremfya® Janssen-Cilag GmbH Skin diseases OTHER Plaque psoriasis 45% Proof of considerable additional benefit
Cenegermin Oxervate® Dompé farmaceutici S.p.A Eye diseases OTHER ORPHAN Neurotrophic keratitis 100% non-quantifiable additional benefit
Telotristatethyl Xermelo® Ipsen Pharma GmbH Oncological diseases OTHER ORPHAN Carcinoid diarrhea 100% non-quantifiable additional benefit
Dimethylfumarat (2) Skilarence® Almirall Hermal GmbH Skin diseases OTHER Plaque psoriasis 100% no additional benefit
Brodalumab Kyntheum® LEO Pharma GmbH Skin diseases OTHER Plaque psoriasis 45% Hint for non-quantifiable additional benefit
Sarilumab Kevzara® Sanofi-Aventis Deutschland GmbH Diseases of the musculoskeletal diseases OTHER Rheumatoid arthritis (RA) 34% Indication for considerable additional benefit
Rolapitant Varuby® TESARO Bio Germany GmbH Other OTHER Nausea & vomiting due to chemotherapy 100% no additional benefit
Tofacitinib Xeljanz® Pfizer Pharma GmbH Diseases of the musculoskeletal diseases OTHER Rheumatoid arthritis (RA) 100% no additional benefit
Baricitinib Olumiant® Lilly Deutschland GmbH Diseases of the musculoskeletal diseases OTHER Rheumatoid arthritis (RA) 100% no additional benefit
Secukinumab (3, reassessment) Cosentyx® Novartis Pharma GmbH Skin diseases OTHER Plaque psoriasis 100% Hint for considerable additional benefit
Ixekizumab Taltz® Lilly Deutschland GmbH Skin diseases OTHER Plaque psoriasis 55% Hint for considerable additional benefit
Reslizumab Cinqaero® Teva GmbH Respiratory diseases OTHER Asthma 50% Indication for minor additional benefit
Migalastat Galafold® Amicus Therapeutics GmbH Metabolic diseases OTHER ORPHAN Morbus Fabry (alpha-galactosidase insuffiency) 100% non-quantifiable additional benefit
Ataluren (2, reassessment) Translarna® PTC Therapeutics International Limited Diseases of the musculoskeletal diseases OTHER ORPHAN Duchenne muscle dystrophia 100% minor additional benefit
Ospemifen Senshio® Shionogi GmbH Diseases of the genitourinary system OTHER Postmenopausal vulvovaginal atrophia (VVA) 100% no additional benefit
Umeclidinium Incruse® GlaxoSmithKline GmbH & Co. KG Respiratory diseases OTHER Chronic obstructive pulmonary disease (COPD) 100% no additional benefit
Mepolizumab Nucala® GlaxoSmithKline GmbH & Co. KG Respiratory diseases OTHER Eosinophilic asthma, severe refractory 50% Indication for minor additional benefit
Secukinumab (2) Cosentyx® Novartis Pharma GmbH Diseases of the musculoskeletal diseases OTHER Psoriatic arthritis, Morbus Bechterew 100% no additional benefit
Aflibercept (6) Eylea® Bayer Vital GmbH Eye diseases OTHER Myopic choroidal neovascularisation 100% no additional benefit
Aclidiniumbromid (2, reassessment) Eklira® Genuair® AstraZeneca GmbH Respiratory diseases OTHER Chronic obstructive pulmonary disease (COPD) 5% Hint for considerable additional benefit
Idebenon Raxone® Santhera Pharmaceuticals Eye diseases OTHER ORPHAN Leber hereditial optic neuropathy (LHON) 100% non-quantifiable additional benefit
Tiotropium / Olodaterol Spiolto® Respimat® Boehringer Ingelheim Pharma GmbH & Co. KG Respiratory diseases OTHER Chronic obstructive pulmonary disease (COPD) 92% Hint for minor additional benefit
Netupitant / Palonosetron Akynzeo® RIEMSER Pharma GmbH Other OTHER Nausea & vomiting due to chemotherapy 100% no additional benefit
Gaxilose LacTest™ VENTER PHARMA S.L. Metabolic diseases OTHER Diagnosis of hypolactasia 100% no additional benefit
Belatacept (2, reassessment) Nulojix® Bristol-Myers Squibb GmbH & Co. KGaA Diseases of the genitourinary system OTHER GvHD after kidney transplantation 100% Hint for considerable additional benefit
Secukinumab Cosentyx® Novartis Pharma GmbH Skin diseases OTHER Plaque psoriasis 8% Hint for considerable additional benefit
Ivermectin Soolantra® Galderma Laboratorium GmbH Skin diseases OTHER Roseacea 100% no additional benefit
Aflibercept (5) Eylea® Bayer Vital GmbH Eye diseases OTHER Diabetic macular edema 100% no additional benefit
Apremilast Otezla® Celgene GmbH Diseases of the musculoskeletal diseases OTHER Plaque psoriasis / psoriatic arthritis 100% no additional benefit
Aclidiniumbromid / Formoterol Duaklir® Genuair® / Brimica® Genuair® AstraZeneca GmbH Respiratory diseases OTHER Chronic obstructive pulmonary disease (COPD) 5% Hint for considerable additional benefit
Tafluprost / Timolol Taptiqom® Santen GmbH Eye diseases OTHER Reduction of intraocular pressure in pat. with glaucoma/hypertension 100% no additional benefit
Sucroferric Oxyhydroxide Velphoro® Fresenius Medical Care Deutschland GmbH Other OTHER Control of phosphate plasma level 100% no additional benefit
Aflibercept (4) Eylea® Bayer Vital GmbH Eye diseases OTHER Diabetic macular edema 100% no additional benefit
Propranolol Hemangiol® Pierre Fabre Dermatologie Other OTHER Infantile hemangioma 33% Hint for major additional benefit
Umeclidinium / Vilanterol Anoro® GlaxoSmithKline GmbH & Co. KG Respiratory diseases OTHER Chronic obstructive pulmonary disease (COPD) 100% no additional benefit
Vedolizumab Entyvio® Takeda Pharma Vertrieb GmbH & Co. KG Diseases of the digestive system OTHER Colitis ulcerosa, Morbus Crohn 100% no additional benefit
Olodaterol Striverdi® Boehringer Ingelheim Pharma GmbH & Co. KG Respiratory diseases OTHER Chronic obstructive pulmonary disease (COPD) 100% no additional benefit
Mirabegron Betmiga® Astellas Pharma GmbH Diseases of the genitourinary system OTHER Imperative desire to urinate 100% no additional benefit
Lebende Larven von Lucilia sericata BioBag® BioMonde GmbH Other OTHER Debridement of chronic severe-healing wounds 100% no additional benefit
Aflibercept (3) Eylea® Bayer Vital GmbH Eye diseases OTHER Macular edema 100% no additional benefit
Nepafenac Nevanac® Alcon Pharma GmbH Eye diseases OTHER Postoperative pain after eye surgery 100% no additional benefit
Fluticasonfuroat / Vilanterol-Trifenatat Relvar® Ellipta® GlaxoSmithKline GmbH & Co. KG Respiratory diseases OTHER Asthma, COPD 100% no additional benefit
Ocriplasmin Jetrea® ThromboGenics NV / Alcon Pharma GmbH Eye diseases OTHER Vitreomacular traction (VMT) 95% Indication for considerable additional benefit
Linaclotid Constella® Almirall Hermal GmbH Diseases of the digestive system OTHER Irritable bowel syndrome (IBS) 100% no additional benefit
Ingenolmebutat Picato® LEO Pharma GmbH Skin diseases OTHER Actinic keratosis 100% no additional benefit
Aflibercept Eylea® Bayer Vital GmbH Eye diseases OTHER Age-related macular degeneration (AMD) 100% no additional benefit
Colestilan BindRen® Mitsubishi Pharma Deutschland GmbH Other OTHER Hyperphosphatemia 100% no additional benefit
Aclidiniumbromid Eklira® Genuair® Almirall Hermal GmbH Respiratory diseases OTHER Chronic obstructive pulmonary disease (COPD) 100% no additional benefit
Belimumab Benlysta® GlaxoSmithKline GmbH & Co. KG Diseases of the musculoskeletal diseases OTHER Systemic Lupus Erythematodes (SLE) 100% Hint for considerable additional benefit
Belatacept Nulojix® Bristol-Myers Squibb GmbH & Co. KGaA Diseases of the genitourinary system OTHER GvHD after kidney transplantation 100% Hint for minor additional benefit
Mikrobielle Collagenase aus Clostridium histolyticum Xiapex® Pfizer Pharma GmbH Diseases of the musculoskeletal diseases OTHER Dupuytren's contracture 100% no additional benefit
Regadenoson Rapiscan® Rapidscan Pharma Solutions EU Ltd. Other OTHER Stress inductor for myocard perfusion 100% no additional benefit
Indacaterol / Glycopyrronium Ultibro Breezhaler® Novartis Pharma GmbH Respiratory diseases OTHER Chronic obstructive pulmonary disease (COPD) 5% Hint for minor additional benefit
Bromfenac Yellox® Bausch & Lomb / Dr. Mann Pharma Eye diseases OTHER Ophthalmitis after cataract extraction 100% no additional benefit